2025-02-14 |
World ADC US 2025 |
2025-02-14 |
World ADC Asia 2025 |
2025-01-14 |
Week 2, January 2025: Antibodies X PROTACs |
2025-01-14 |
Antibody-Drug Conjugates: Transforming the Biopharma Landscape |
2025-01-03 |
15th Annual World ADC – London 2025 |
2024-11-19 |
Antibody-Drug Conjugates: Microtubule Inhibitors, DNA Binders, and Topoisomerase Inhibitors |
2024-10-28 |
What is ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity)? |
2024-10-24 |
What are Antibody-Drug Conjugates? |
2024-10-22 |
Week 4, October 2024: Further than ADCs? |
2024-10-22 |
The Evolution of Antibody-Drug Conjugates (ADCs) in Cancer Therapy |
2024-10-19 |
Antibody-Drug Conjugates (ADCs) and Drug–Antibody Ratio (DAR) |
2024-10-08 |
Week 2, October 2024: ADCs in Regulatory Review |
2024-10-06 |
Antibody-Drug Conjugates and Immune Checkpoint Inhibitors in Cancer Treatment |
2024-09-26 |
What is Antibody Drug Development? |
2024-09-13 |
What are Innovative Antibody Formats? |
2024-09-06 |
Antibody Effector Functions |
2024-08-26 |
Understanding the Difference Between ADC Biosimilars and ADC Isotypes |
2024-08-20 |
Precision In Vivo Research: How ADCs Make the Difference |
2024-08-13 |
Week 2, August 2024: Hepatitis B Virus (HBV) |
2024-08-07 |
BIO Asia 2024 – Taiwan: Highlights and Event Recap |
2024-08-06 |
Week 1, August 2024: ADCs: Funding Trends |
2024-08-03 |
BIX (BIOPLUS INTERPHEX KOREA): Technology Highlights |
2024-07-30 |
Week 5, July 2024: ADCs & Gynecologic Cancer |
2024-07-26 |
Antibody-Mediated Phagocytosis Against Cancer |
2024-07-24 |
Antibody-Drug Conjugates: A Brief |
2024-07-16 |
Week 3, July 2024: Immunostimulatory ADCs (iADCs) |
2024-06-25 |
Week 4, June 2024: Immune Checkpoint Blockade |
2024-06-19 |
Afucosylated Antibodies: Mechanism of Action and Therapeutic Applications |
2024-06-17 |
Types of Payloads for Antibody-Drug Conjugates (ADCs) |
2024-06-14 |
Multi-Payload Antibody–Drug Conjugates |